B+
Bull case
25%
Probability
Target price
$118.00
Analysis reference price unavailable
Analysis 2026-09-04 · RankAlpha Sentiment Codex
GMED
Globus MedicalANYSE / Health Care Equipment & Services
Last Price
Quote time unavailable
AI scenario view
RankAlpha Sentiment CodexMost likely
B
Base case
50%
Probability
Target price
$103.23
Analysis reference price unavailable
Analysis 2026-09-04 · RankAlpha Sentiment Codex
B-
Bear case
25%
Probability
Target price
$67.00
Analysis reference price unavailable
Analysis 2026-09-04 · RankAlpha Sentiment Codex
The current persistence contract does not provide an exact AI reference price. RankAlpha therefore does not calculate scenario return from the live quote. How scenarios are presented
AI sentiment snapshot
Latest data as of 2026-09-04
Recent news sentiment (30D)
0.0
Mixed
Company
-
Unavailable
Macro
-
Unavailable
Pulse
-
Unavailable
Weekly research (10D)
+30.0
Positive
Sentiment proxy
+100.0
Score
AI commentary
Primary-source earnings evidence is positive, but the recent-news packet contains no GMED-specific coverage, social data, options data, short-interest data, employee-rating data, or verified analyst revisions. Sentiment therefore reflects fundamentals more than current market narrative; maintain a cautious monitoring bias.
RankAlpha Sentiment Codex - 2026-09-04
Open full AI memoEvidence flagged
No evidence quality warning is currently attached to this memo.
Impact
standard
Confidence
-
AI events
2026-08-06eventQ2 2026 earnings and raised EPS outlookMedium impact
Q2 revenue rose 5.9% to $789.6 million, or 9% excluding Nevro; non-GAAP diluted EPS increased 55.8% to $1.34. Management reaffirmed FY2026 revenue guidance of $3.18-$3.22 billion and raised non-GAAP EPS guidance to $4.95-$5.05 from $4.70-$4.80. [#SEC-8K-2026-08-06]
2026-12-31catalystCore portfolio and enabling-technology executionHigh impact
The Q1 release cited procedural-volume strength in core Spine and continued Enabling Technologies pipeline and customer-base expansion, providing a forward execution hook, though current-quarter detail and dated milestones are limited. [#SEC-8K-2026-05-07]
2027-09-04catalystSustained spine share gains and operating leverageHigh impact
Management cited fifth consecutive quarter of above-market US Spine growth, 7% US Spine growth, 14% reported international Spine growth, 200 basis points of adjusted gross-margin expansion, operating leverage, and synergy realization. [#SEC-8K-2026-08-06]
Recommendation
N/A
No formal recommendation provided.
As of 2026-09-04 • Updated nightlySource: Internal modelMethodology